Standout Papers

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib:... 2012 2026 2016 2021 417
  1. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial (2012)
    Jeffrey R. Infante, Leslie A. Fecher et al. The Lancet Oncology

Immediate Impact

5 from Science/Nature 56 standout
Sub-graph 1 of 21

Citing Papers

A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
2024 Standout
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
2024 Standout
22 intermediate papers

Works of Vijay Peddareddigari being referenced

Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
2018
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
2012 Standout

Author Peers

Author Last Decade Papers Cites
Vijay Peddareddigari 592 705 112 179 18 1.1k
Lidia Moserle 487 640 169 111 25 1.1k
Laith Dabbagh 539 546 209 188 23 1.3k
Katrin E. Rhodes 555 568 150 310 21 1.3k
Giorgia Migliardi 710 507 95 346 28 1.3k
Gilbert O’Young 577 711 179 145 22 1.4k
Cristina Basilico 347 664 127 144 31 1.3k
Ricardo Costa 397 489 109 209 17 1.0k
Sujatha Jagadeeswaran 357 457 99 166 16 959
Ivan Ischenko 505 619 87 140 22 1.2k
J. Rafael Sierra 357 571 192 245 18 1.1k

All Works

Loading papers...

Rankless by CCL
2026